title: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
abstract: BACKGROUND
  CD4+ lymphocyte counts and plasma HIV-1 RNA levels predict progression of HIV-related disease, but the relative importance of these and other virological factors in defining response to antiretroviral therapy is not yet clear.
  
  
  OBJECTIVE
  To determine the short-term variability of plasma HIV-1 RNA level during stable therapy; the relative importance of pretreatment values and early changes in CD4+ count, HIV-1 RNA levels, and infectious HIV-1 titers in mononuclear cells of peripheral blood and pretreatment syncytium-inducing phenotype of an HIV-1 isolate for prediction of disease progression and decline in CD4+ counts during therapy.
  
  
  METHODS
  Data were collected prospectively in a randomized, clinical trial comparing two combination regimens (ACTG [AIDS Clinical Trials Group] Protocol 241) and pooled across treatments.
  
  
  METHODS
  8 AIDS Clinical Trials Units.
  
  
  METHODS
  198 adults with HIV-1 infection and no more than 350 CD4+ lymphocytes/mm3 who had received at least 6 months of nucleoside therapy.
  
  
  METHODS
  All patients received zidovudine and didanosine; 100 received nevirapine and 98 received placebo.
  
  
  METHODS
  CD4+ lymphocyte counts, plasma HIV-1 RNA levels, and infectious HIV-1 titers in cells were measured before and 8 and 48 weeks after study treatment. Assay for the syncytium-inducing viral phenotype was done at baseline. Progression was defined as occurrence of opportunistic infection, malignancy, or death during the 48 weeks after treatment began.
  
  
  RESULTS
  The difference between two measurements of HIV-1 RNA levels at baseline was within +/-0.39 log10 copies/mL (2.5-fold) for 90% of 167 patients receiving stable therapy. In a multivariate model, risk for disease progression was reduced by 56% (95% CI, 8% to 79% [P = 0.028]) for every 10-fold lower HIV-1 RNA level at baseline, by 52% (CI, 6% increase to 79% reduction [P = 0.071]) for every 10-fold reduction in HIV-1 RNA level at 8 weeks after treatment initiation, and by 67% (CI, 42% to 81% [P < 0.001]) for every 2-fold higher CD4+ count at baseline. These risk factors and syncytium-inducing viral phenotype at baseline, but not infectious HIV-1 titers in circulating cells, were associated with change in CD4+ counts over 48 weeks.
  
  
  CONCLUSIONS
  For an individual patient, a change in plasma HIV-1 RNA level of 2.5-fold or more probably indicates a true biological change. Monitoring HIV-1 RNA levels and CD4+ lymphocytes before a change in antiretroviral treatment and monitoring HIV-1 RNA levels shortly thereafter improves prediction of disease progression and decline in CD4+ counts for 1 year compared with monitoring CD4+ counts of HIV-1 RNA levels alone. Additional monitoring of infectious HIV-1 titers in mononuclear cells of peripheral blood is not useful.
authors.affiliation: Harvard School of Public Health, Massachusetts General Hospital, Boston 02114-2698, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Hughes
authors.forename: V A
authors.initials: VA
authors.lastname: Johnson
authors.forename: M S
authors.initials: MS
authors.lastname: Hirsch
authors.forename: J W
authors.initials: JW
authors.lastname: Bremer
authors.forename: T
authors.initials: T
authors.lastname: Elbeik
authors.forename: A
authors.initials: A
authors.lastname: Erice
authors.forename: D R
authors.initials: DR
authors.lastname: Kuritzkes
authors.forename: W A
authors.initials: WA
authors.lastname: Scott
authors.forename: S A
authors.initials: SA
authors.lastname: Spector
authors.forename: N
authors.initials: N
authors.lastname: Basgoz
authors.forename: M A
authors.initials: MA
authors.lastname: Fischl
authors.forename: R T
authors.initials: RT
authors.lastname: D'Aquila
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000097:blood* / Q000188:drug therapy* / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods*; D019829:Nevirapine; D010641:Phenotype; D011446:Prospective Studies; D011725:Pyridines / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D011725:Pyridines; D012367:RNA, Viral; D015215:Zidovudine; D019829:Nevirapine; D016049:Didanosine